AlphAIAlphAI — Financial news for AI agents
rttnews.comOCT 92 min read$JNJ

Johnson & Johnson Reports Sustained Two-Year ICOTYDE Results In Plaque Psoriasis

Johnson & Johnson (JNJ) reported two-year results from its Phase 3 ICONIC-LEAD study of ICOTYDE for plaque psoriasis, showing sustained skin clearance and symptom improvements. At Week 112, 72% of patients achieved PASI 90, 70% had clear/almost clear skin, and 44% had complete clearance. Safety findings were consistent with the drug's profile. JNJ is also studying ICOTYDE for other conditions. JNJ closed at $256.48, down 0.76%, and was down 0.15% in premarket trading.

Original reporting
rttnews.com
Published Oct 9, 2026, 12:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 12:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Johnson & Johnson Reports Sustained Two-Year ICOTYDE Results In Plaque Psoriasis — source image
Source · rttnews.com
Decision brief

The 30-second read

$JNJNeutralMed
01

Why it matters

The trial results reinforce the drug's efficacy, but the immediate price reaction was a slight decline, suggesting the market may be waiting for further data or commercial rollout details.

02

Market read

The data are material for JNJ's dermatology franchise and may influence analyst outlooks, but immediate trading impact appears modest.

03

What to watch

Potential regulatory timeline, competition from other IL‑23 inhibitors, and reimbursement considerations could temper upside.

Relevance 7/10Novelty 9/10Timing: pre‑market today

Background

Johnson & Johnson is a diversified health‑care conglomerate; ICOTYDE is its oral IL‑23 antagonist for moderate‑to‑severe plaque psoriasis, recently approved in the U.S.

Company-level read

Ticker impact

$JNJNeutralHigh confidence
Context

Johnson & Johnson disclosed Phase 3 ICONIC-LEAD trial results for ICOTYDE, showing sustained PASI 90/100 responses through Week 112.

Expected impact

modest downside as the market digests the data and the pre‑market price decline

Evidence & confidence

The data are favorable yet the stock opened lower, indicating traders may be cautious pending regulatory filing or broader market context.

Market effects

Sector

Positive Phase 3 data could boost sentiment for the broader dermatology/psoriasis therapeutic segment.

Regional

Minimal; impact confined to U.S. and global biotech equities.

Global

Limited to investors tracking large‑cap pharma pipelines.

Counterpoint

What could challenge this read

Despite strong efficacy, the modest pre‑market dip may signal concerns about commercialization or pricing pressures.

Key entities

  • company
    Johnson & Johnson

    US‑listed healthcare conglomerate (ticker JNJ).

  • product
    ICOTYDE

    Oral peptide IL‑23 receptor antagonist for plaque psoriasis.

Read at source← All news

Also covered by

1 outlet

Related articles

OCT 9
$JNJMed

Johnson & Johnson Reports Positive Two-Year Data on ICOTYDE for

Johnson & Johnson (JNJ) reported positive two-year Phase 3 trial results for ICOTYDE, an oral peptide for plaque psoriasis, with 72% of patients achieving significant skin improvement. The company offers a 1.98% dividend yield, a 55% payout ratio, and a 4.9% 3-year dividend growth rate, but its stock is 32% overvalued relative to its GF Value. JNJ has a GF Score of 83/100, indicating strong financial health and profitability, though insider activity shows significant net selling.

gurufocus.com3 min
OCT 9
$JNJMed

New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis

Johnson & Johnson (JNJ) presented two-year Phase 3 data for ICOTYDE® (icotrokinra) at Fall Clinical Dermatology 2026. The study showed high, sustained response rates in adults and adolescents with plaque psoriasis, with 72% achieving clear or almost clear skin and a favorable safety profile. ICOTYDE is the first targeted oral peptide blocking the IL-23 receptor. The company highlights its potential as a first-line systemic therapy.

prnewswire.com2 min